BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bergasa NV, Vergalla J, Swain MG, Jones EA. Hepatic concentrations of proenkephalin-derived opioids are increased in a rat model of cholestasis. Liver 1996;16:298-302. [DOI: 10.1111/j.1600-0676.1996.tb00749.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Ho V, Stewart M, Boyd P. Cholestatic hepatitis as a possible new side-effect of oxycodone: a case report. J Med Case Rep 2008;2:140. [PMID: 18452597 DOI: 10.1186/1752-1947-2-140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Bergasa NV. The pruritus of cholestasis: From bile acids to opiate agonists: Relevant after all these years. Medical Hypotheses 2018;110:86-9. [DOI: 10.1016/j.mehy.2017.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
3 Bergasa N, Liau S, Homel P, Ghali V. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis: Met-enkephalin in PBC livers. Liver 2002;22:107-13. [DOI: 10.1034/j.1600-0676.2002.01458.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
4 Sanjel B, Maeng HJ, Shim WS. BAM8-22 and its receptor MRGPRX1 may attribute to cholestatic pruritus. Sci Rep 2019;9:10888. [PMID: 31350433 DOI: 10.1038/s41598-019-47267-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
5 Düll MM, Kremer AE. Treatment of Pruritus Secondary to Liver Disease. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0713-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
6 Riazi K, Honar H, Homayoun H, Demehri S, Bahadori M, Dehpour AR. Intestinal inflammation alters the susceptibility to pentylenetetrazole-induced seizure in mice. J Gastroenterol Hepatol 2004;19:270-7. [PMID: 14748873 DOI: 10.1111/j.1440-1746.2003.03284.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
7 McRae CA, Prince MI, Hudson M, Day CP, James OF, Jones DE. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003;125:591-6. [PMID: 12891561 DOI: 10.1016/s0016-5085(03)00879-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
8 Marzioni M, Alpini G, Saccomanno S, de Minicis S, Glaser S, Francis H, Trozzi L, Venter J, Orlando F, Fava G, Candelaresi C, Macarri G, Benedetti A. Endogenous Opioids Modulate the Growth of the Biliary Tree in the Course of Cholestasis. Gastroenterology 2006;130:1831-47. [DOI: 10.1053/j.gastro.2006.02.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 77] [Article Influence: 2.0] [Reference Citation Analysis]
9 Marzioni M, Invernizzi P, Candelaresi C, Maggioni M, Saccomanno S, Selmi C, Rychlicki C, Agostinelli L, Cassani B, Miozzo M, Pasini S, Fava G, Alpini G, Benedetti A. Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. Dig Liver Dis 2009;41:523-33. [PMID: 18948067 DOI: 10.1016/j.dld.2008.09.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 59] [Article Influence: 0.6] [Reference Citation Analysis]
10 Sanjel B, Shim WS. Recent advances in understanding the molecular mechanisms of cholestatic pruritus: A review. Biochim Biophys Acta Mol Basis Dis 2020;1866:165958. [PMID: 32896605 DOI: 10.1016/j.bbadis.2020.165958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Fagan EA. Intrahepatic cholestasis of pregnancy. Clin Liver Dis 1999;3:603-32. [PMID: 11291241 DOI: 10.1016/s1089-3261(05)70087-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
12 Olson GA, Olson RD, Kastin AJ. Endogenous Opiates: 1996. Peptides 1997;18:1651-88. [DOI: 10.1016/s0196-9781(97)00264-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
13 Jensen K, Marzioni M, Munshi K, Afroze S, Alpini G, Glaser S. Autocrine regulation of biliary pathology by activated cholangiocytes. Am J Physiol Gastrointest Liver Physiol 2012;302:G473-83. [PMID: 22194419 DOI: 10.1152/ajpgi.00482.2011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
14 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:28:2:147] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
15 Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Karrer FM. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999;29:442-7. [PMID: 10512405 DOI: 10.1097/00005176-199910000-00013] [Cited by in Crossref: 73] [Cited by in F6Publishing: 53] [Article Influence: 3.2] [Reference Citation Analysis]
16 Düll MM, Kremer AE. Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease. Curr Hepatology Rep 2020;19:86-95. [DOI: 10.1007/s11901-020-00517-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kremer AE, Feramisco J, Reeh PW, Beuers U, Oude Elferink RP. Receptors, cells and circuits involved in pruritus of systemic disorders. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2014;1842:869-92. [DOI: 10.1016/j.bbadis.2014.02.007] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
18 Zellos A, Roy A, Schwarz KB. Use of oral naltrexone for severe pruritus due to cholestatic liver disease in children. J Pediatr Gastroenterol Nutr 2010;51:787-9. [PMID: 20948447 DOI: 10.1097/MPG.0b013e3181eb5ac0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
19 Marzioni M, Saccomanno S, Candelaresi C, Rychlicki C, Agostinelli L, Trozzi L, De Minicis S, Benedetti A. Clinical implications of novel aspects of biliary pathophysiology. Dig Liver Dis 2010;42:238-44. [PMID: 20167547 DOI: 10.1016/j.dld.2010.01.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
20 Javadi-Paydar M, Ghiassy B, Ebadian S, Rahimi N, Norouzi A, Dehpour AR. Nitric oxide mediates the beneficial effect of chronic naltrexone on cholestasis-induced memory impairment in male rats. Behav Pharmacol 2013;24:195-206. [PMID: 23591123 DOI: 10.1097/FBP.0b013e3283618a8c] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
21 Bergasa NV. Medical palliation of the jaundiced patient with pruritus. Gastroenterol Clin North Am. 2006;35:113-123. [PMID: 16530114 DOI: 10.1016/j.gtc.2005.12.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
22 Payabvash S, Kiumehr S, Nezami BG, Zandieh A, Anvari P, Tavangar SM, Dehpour AR. Endogenous opioids modulate hepatocyte apoptosis in a rat model of chronic cholestasis: the role of oxidative stress. Liver Int 2007;27:538-47. [PMID: 17403194 DOI: 10.1111/j.1478-3231.2007.01457.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
23 Bergasa NV. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin Liver Dis. 2008;12:385-406; x. [PMID: 18456187 DOI: 10.1016/j.cld.2008.02.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
24 Floreani A, Antoniazzi S, Mescoli C, Bergasa NV. Hepatic Methionine-enkephalin may interfere with response to antiviral therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 2012;24:427-30. [PMID: 22293330 DOI: 10.1097/MEG.0b013e3283509197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
25 Hegade VS, Bolier R, Oude Elferink RP, Beuers U, Kendrick S, Jones DE. A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. Frontline Gastroenterol 2016;7:158-66. [PMID: 28839853 DOI: 10.1136/flgastro-2015-100618] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
26 Nasehi M, Kafi F, Zarrindast M. Differential mechanisms of opioidergic and dopaminergic systems of the ventral hippocampus (CA3) in anxiolytic-like behaviors induced by cholestasis in mice. European Journal of Pharmacology 2013;714:352-8. [DOI: 10.1016/j.ejphar.2013.07.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
27 Day SA, Lakner AM, Moore CC, Yen MH, Clemens MG, Wu ES, Schrum LW. Opioid-like compound exerts anti-fibrotic activity via decreased hepatic stellate cell activation and inflammation. Biochem Pharmacol. 2011;81:996-1003. [PMID: 21291870 DOI: 10.1016/j.bcp.2011.01.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
28 Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol. 2011;35:89-97. [PMID: 21809485 DOI: 10.1016/j.clinre.2010.10.007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
29 Düll MM, Wolf K, Vetter M, Dietrich P, Neurath MF, Kremer AE. Endogenous Opioid Levels Do Not Correlate With Itch Intensity and Therapeutic Interventions in Hepatic Pruritus. Front Med (Lausanne) 2021;8:641163. [PMID: 33937284 DOI: 10.3389/fmed.2021.641163] [Reference Citation Analysis]
30 Hegade VS, Kendrick SF, Jones DE. Drug treatment of pruritus in liver diseases. Clin Med (Lond) 2015;15:351-7. [PMID: 26407384 DOI: 10.7861/clinmedicine.15-4-351] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
31 Wang H, Yosipovitch G. New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol 2010;49:1-11. [PMID: 20465602 DOI: 10.1111/j.1365-4632.2009.04249.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
32 Imam MH, Gossard AA, Sinakos E, Lindor KD. Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol. 2012;27:1150-1158. [PMID: 22413872 DOI: 10.1111/j.1440-1746.2012.07109.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
33 Eslimi D, Oryan S, Nasehi M, Zarrindast MR. Effects of opioidergic systems upon anxiolytic-like behaviors induced in cholestatic rats. European Journal of Pharmacology 2011;670:180-5. [DOI: 10.1016/j.ejphar.2011.08.024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
34 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Oude Elferink RP, Kremer AE, Beuers U. Mediators of pruritus during cholestasis. Curr Opin Gastroenterol. 2011;27:289-293. [PMID: 21451412 DOI: 10.1097/mog.0b013e32834575e8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
36 Jones E, Zylicz Z. Treatment of Pruritus Caused by Cholestasis with Opioid Antagonists. Journal of Palliative Medicine 2005;8:1290-4. [DOI: 10.1089/jpm.2005.8.1290] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
37 Marzioni M, Fava G, Alvaro D, Alpini G, Benedetti A. Control of cholangiocyte adaptive responses by visceral hormones and neuropeptides. Clin Rev Allergy Immunol. 2009;36:13-22. [PMID: 18548352 DOI: 10.1007/s12016-008-8090-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
38 Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163-2182. [PMID: 18840005 DOI: 10.2165/00003495-200868150-00006] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
39 Faramarzi N, Abbasi A, Tavangar SM, Mazouchi M, Dehpour AR. Opioid receptor antagonist promotes angiogenesis in bile duct ligated rats. J Gastroenterol Hepatol 2009;24:1226-9. [PMID: 19486259 DOI: 10.1111/j.1440-1746.2009.05794.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
40 Hasanein P, Parviz M, Keshavarz M, Javanmardi K, Allahtavakoli M, Ghaseminejad M. Modulation of cholestasis-induced antinociception in rats by two NMDA receptor antagonists: MK-801 and magnesium sulfate. Eur J Pharmacol 2007;554:123-7. [PMID: 17107671 DOI: 10.1016/j.ejphar.2006.10.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]